[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100465814":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":63,"collaborators":42,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":42,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":42,"enrollmentInfo":75,"targetDuration":42,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":42,"overallStatus":50,"whyStopped":42,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Assaf-Harofeh Medical Center","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tranexamic Acid group","EXPERIMENTAL","standard solution for injection with TXA and without adrenaline",[13],"Drug: Tranexamic acid",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard therapy group","PLACEBO_COMPARATOR","standard solution for injection including adrenaline",[19],"Drug: Standard",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tranexamic acid","Submucosal injection of standard solution including TXA during EMR procedure",[9],[27],"TXA, Cyklokapron",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Standard","Injection of standard solution",[15],[33],"adrenaline, epinephrine",[35],{"name":36,"affiliation":5,"role":37},"Anton Bermont, MD","PRINCIPAL_INVESTIGATOR",[39,44],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","+972526944145",null,"bermont@doctor.com",{"name":45,"role":40,"phone":42,"phoneExt":42,"email":46},"Sergei Vosko, MD","sergeivosko@gmail.com",[48],{"facility":49,"status":50,"city":51,"state":42,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Shamir Medical Center","RECRUITING","Be’er Ya‘aqov","70300","Israel","IL",{"type":56,"coordinates":57},"Point",[58,59],34.83749,31.93864,{"lat":59,"lon":58},[62],{"name":36,"role":40,"phone":42,"phoneExt":42,"email":42},{"type":37,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Anton Bermont","Doctor","100465814","phase-4-tranexamic-acid-during-colonic-endoscopic-resection-procedures-100465814",false,"NCT05345613","Tranexamic Acid During Colonic Endoscopic Resection Procedures","Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding","Inclusion Criteria:\n\n* Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center.\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* patients with histories of allergic reactions to TXA\n* history of seizures\n* pregnancy","ALL","18 Years",{"count":76,"type":77},200,"ESTIMATED","INTERVENTIONAL",[80],"PHASE4","Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.",[83],"Colon Neoplasm","2026-01-10",{"date":86,"type":87},"2026-01-13","ACTUAL",{"date":89,"type":87},"2022-05-01",{"date":91,"type":77},"2026-10-01",{"name":5,"class":6},1]